Drugs / TT-00973-MS
last change Dec 2025 re-read 3 minutes ago

TT-00973-MS

Developed for
neoplasm
Investigated by
TransThera Sciences (Nanjing), Inc.

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05673538 Jan 2023 → Dec 2024 neoplasm TransThera Sciences (Nanjing), Inc. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TT-00973-MS ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673538 ↗